The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Clinical and infusion product characteristics influencing the outcomes and toxicity of CAR T-cell treatment with axicabtagene ciloleucel for LBCL
Chimeric antigen receptor (CAR) T-cell therapy represents a novel treatment for the management of...
Nov 25, 2020
|DLBCL
Gilles Salles
"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology."